Latest erenumab trial signals hope for refractory migraine sufferers

Written by Roisin Conneely

Amgen (CA, USA) has announced finding from its latest trial investigating the drug Aimovig™ (erenumab) for the treatment of episodic migraines in patients who have not responded to previous treatment. The drug is currently the only experimental fully-human monoclonal antibody, designed to target and inhibit the CGRP receptor, which is critical in the activation of migraines. The Phase IIIb LIBERTY study was carried out over 12 weeks, across 65 locations throughout Europe and Australia, enrolling 246 participants. All were sufferers of episodic migraines, defined as four to 14 migraine days per month, with two to four treatment failures. Participants were...

To view this content, please register now for access

It's completely free